Related Experiment Video
Updated: Dec 19, 2025
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
669
A report from the 8th Kuopio Alzheimer Symposium
Annakaisa Haapasalo1, Mikko Hiltunen2
1A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Neurodegenerative Disease Management
|August 17, 2018
Summary
The 8th International Kuopio Alzheimer Symposium convened 300 global researchers to discuss Alzheimer's disease mechanisms, comorbidities, and novel therapeutic strategies for neurodegenerative diseases.
Area of Science:
- Neuroscience
- Neurology
Background:
- The 8th International Kuopio Alzheimer Symposium convened in Kuopio, Finland, June 6-8, 2018.
- Approximately 300 international researchers in neuroscience and neurology attended.
- The symposium focused on Alzheimer's disease and other neurodegenerative diseases.
Framework:
- A 2-day international program featured a keynote session, five oral scientific sessions, and a poster session.
- Discussions centered on the latest insights into disease mechanisms and comorbidities.
- Novel approaches for diagnosis, prediction, prevention, and therapies were explored.
Implementation:
- The symposium was organized by the University of Eastern Finland.
- It included a preceding 'Memory Day' on June 6 for Finnish healthcare professionals.
- The 'Memory Day' was conducted in Finnish, targeting doctors, psychologists, and nurses.
Implications:
- Fostered collaboration and knowledge exchange among global experts in Alzheimer's and neurodegenerative diseases.
- Highlighted advancements in understanding and treating complex neurological conditions.
- Aimed to improve patient care through updated diagnostic and therapeutic strategies.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
675
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
675
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
01:30Dementia
438
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
438
01:24Parkinson's Disease: Treatment
842
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
842
01:15Parkinson's Disease: Overview
1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K